Boston Scientific’s (BSX) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Boston Scientific (NYSE:BSX) in a report published on Thursday,Benzinga reports. Needham & Company LLC currently has a $121.00 price target on the medical equipment provider’s stock.

A number of other research analysts have also weighed in on the stock. Citigroup reiterated a “buy” rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Truist Financial lifted their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Leerink Partners initiated coverage on shares of Boston Scientific in a research note on Monday, June 16th. They issued an “outperform” rating and a $118.00 price objective for the company. Finally, Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $118.04.

Boston Scientific Trading Down 1.6%

Shares of BSX stock opened at $102.71 on Thursday. The company has a 50 day moving average of $104.86 and a 200-day moving average of $102.26. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific has a 12-month low of $80.64 and a 12-month high of $109.50. The firm has a market cap of $152.19 billion, a P/E ratio of 61.14, a PEG ratio of 2.51 and a beta of 0.65.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the business posted $0.62 EPS. Boston Scientific’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 in the last quarter. 0.50% of the stock is currently owned by company insiders.

Institutional Trading of Boston Scientific

Hedge funds have recently made changes to their positions in the stock. NS Partners Ltd lifted its holdings in shares of Boston Scientific by 1.6% during the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after acquiring an additional 5,704 shares during the last quarter. Reliant Investment Partners LLC bought a new stake in shares of Boston Scientific during the 1st quarter worth $237,000. Bank Pictet & Cie Europe AG lifted its holdings in shares of Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock worth $6,529,000 after acquiring an additional 21,173 shares during the last quarter. Ascent Group LLC lifted its holdings in shares of Boston Scientific by 226.5% during the 1st quarter. Ascent Group LLC now owns 49,942 shares of the medical equipment provider’s stock worth $5,038,000 after acquiring an additional 34,645 shares during the last quarter. Finally, Axiom Investors LLC DE lifted its holdings in shares of Boston Scientific by 26.8% during the 1st quarter. Axiom Investors LLC DE now owns 4,759,258 shares of the medical equipment provider’s stock worth $480,114,000 after acquiring an additional 1,006,828 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.